Decoding the Role of an Alzheimer's Causal Gene in Distinct Brain Cell Types
About the Research Project
Program
Award Type
Standard
Award Amount
$300,000
Active Dates
July 01, 2024 - June 30, 2027
Grant ID
A2024033S
Goals
We will combine new chimeric human-mouse models with in vitro human neurons and microglia, to unravel the cell type specific contributions of the causal gene, presenilin2 in AD etiopathogenesis.
Summary
Mutations in the gene encoding presenilin2 (PSEN2) cause early onset familial Alzheimer’s disease but thus far this was mainly studied in the context of a build-up of toxic amyloid aggregates. However given its restricted localization in degradative compartments, we hypothesize that mechanisms exist leading to disease onset that may differ from its close relative PSEN1. Utilizing new PSEN2 AD mouse models and human neurons/microglia, we will employ functional assays and advanced morphological studies to unravel the cell type specific contributions of PSEN2 in AD etiopathogenesis.
Unique and Innovative
We hypothesize that the mechanisms by which PSEN2 mutations contribute to etiopathogenesis may differ from PSEN1- and APP-linked mutations. This project will uniquely explore this from the brain tissue level down to the cellular level in neurons and glia. Herein, it focuses on underlying molecular defects in lysosomes, the ‘waste bins’ of cells required for neuronal survival. Experimentally, we combine functional readouts for brain circuits, with most advanced imaging technologies in vivo and in human cell models, and innovative transcriptomics to map brain changes at single cell resolution.
Foreseeable Benefits
Research has focused on the major causal genes, PSEN1 and the amyloid precursor protein, ignoring the more rare PSEN2 mutations. As such, this project will provide a comprehensive picture with unprecedented insights in the contribution of PSEN2 in Alzheimer disease pathology; and this from a molecular and mechanistic level up to functional brain circuits particularly vulnerable in Alzheimer’s disease pathogenesis. The outlined strategies, if successful, may as well have the potential to identify novel therapeutic strategies to tackle these rare cases of PSEN2-associated Alzheimer disease.
Grants
Related Grants
Alzheimer's Disease Research
Evaluating the Role of the TDP-43 Protein in Alzheimer's Disease Pathogenesis
Active Dates
July 01, 2024 - June 30, 2027
Principal Investigator
Mercedes Prudencio, PhD
Evaluating the Role of the TDP-43 Protein in Alzheimer's Disease Pathogenesis
Active Dates
July 01, 2024 - June 30, 2027
Principal Investigator
Mercedes Prudencio, PhD
Alzheimer's Disease Research
Nuclear Material Transfer in Pathogenic Protein Spreading
Active Dates
July 01, 2023 - June 30, 2026
Principal Investigator
Olga Chechneva, PhD
Nuclear Material Transfer in Pathogenic Protein Spreading
Active Dates
July 01, 2023 - June 30, 2026
Principal Investigator
Olga Chechneva, PhD
Alzheimer's Disease Research
Drivers of Vulnerability to Alzheimer’s Disease Neuropathological Changes
Active Dates
July 01, 2022 - June 30, 2025
Principal Investigator
Nicole Liachko, PhD
Drivers of Vulnerability to Alzheimer’s Disease Neuropathological Changes
Active Dates
July 01, 2022 - June 30, 2025
Principal Investigator
Nicole Liachko, PhD